INTRODUCTION
============

Pneumonia is one of the most common infectious diseases requiring admission to the intensive care unit (ICU) for medical treatment. With an aging population, the number of patients who receive care at facilities other than hospitals, such as long-term healthcare facilities, assisted-living environments, or rehabilitation facilities are increasing. Therefore, the traditional classifications for pneumonia based on the patient's location before admission such as community-acquired pneumonia (CAP) or hospital-acquired pneumonia (HAP) needed to be updated \[[@b1-kjim-2015-103],[@b2-kjim-2015-103]\], consequently, a new term, healthcare-associated pneumonia (HCAP) was introduced by the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) in 2005 \[[@b3-kjim-2015-103]\].

Patients who develop HCAP are more similar to hospitalised patients than to independently living community-based patients, in that they have a greater burden of comorbidities, including cancer, chronic kidney disease, heart disease, chronic obstructive lung disease, immunosuppression, dementia, and impaired mobility \[[@b1-kjim-2015-103],[@b3-kjim-2015-103],[@b4-kjim-2015-103]\]. These diverse spectra of HCAP patients may result in varied epidemiology and patient-specific risks for antibiotic-resistant pathogens \[[@b5-kjim-2015-103]-[@b7-kjim-2015-103]\].

To address this, the IDSA/ATS guidelines recommend broad empirical antibiotic therapy followed by culture-guided de-escalation for patients with HCAP \[[@b3-kjim-2015-103]\]. However, despite an excellent negative predictive value (96%), the IDSA/ATS criteria have a low positive predictive value (18%) for differentiating a true infection or colonization with multidrug-resistant (MDR) bacteria in patients with HCAP who admitted to the ICU \[[@b8-kjim-2015-103]\]. Therefore, the adherence to these guidelines is not required in all cases and is able to result in the overuse of antibiotics \[[@b9-kjim-2015-103]\]. Moreover, the current approach to HCAP treatment is also in the need of revision \[[@b10-kjim-2015-103]-[@b12-kjim-2015-103]\].

Herein, we tried to determine the differences in the presence of antibiotic-resistant organisms and clinical outcomes in HCAP patients who need ICU care, compared with CAP and HAP patients.

METHODS
=======

Study subjects and design
-------------------------

From March 2011 to February 2013, we conducted a prospective cohort in a 16-bed medical ICU and a retrospective analysis of patients who required an ICU admission for pneumonia. A clinical diagnosis of pneumonia required the presence of new radiographic infiltrates and at least 2 of the following clinical criteria: fever (\> 38°C) or hypothermia (≤ 35°C), new cough with or without sputum production, pleuritic chest pain, dyspnoea, or altered breath sounds on auscultation. We excluded patients with a documented do-not resuscitate order. The decision of admission to ICU was done in the case of who was required for close monitoring with septic shock under vasopressor or acute respiratory failure requiring intubation and mechanical ventilation \[[@b3-kjim-2015-103]\].

We define HAP as pneumonia that developed after being hospitalised for \> 48 to 72 hours and HCAP as pneumonia that also met at least 1 of the following criteria: (1) recent history of hospitalisation for ≥ 2 days within 90 days of the infection; (2) residence in a nursing home or long-term care facility; (3) recent intravenous antibiotic therapy, chemotherapy, or wound care within 30 days prior to the current infection; or (4) attendance at a haemodialysis clinic \[[@b3-kjim-2015-103]\]. Patients with pneumonia who did not meet any of the criteria for HCAP or HAP were identified as having CAP. We compared clinical characteristics, pneumonia severity, the distribution of pathogens, and outcomes between the three groups (CAP, HCAP, and HAP). If patients admitted to the ICU for pneumonia ≥ 2 times during one hospital admission, only the first event of pneumonia was included. The Institutional Review Board Committee of Seoul National University Bundang Hospital waived the informed consent in this study (No. B-1105/127-001).

Microbiological studies
-----------------------

At the day of ICU admission, microbiological studies were conducted using two sets of blood culture samples, gram staining and culture using the transendotracheal aspirate or sputum from patients without intubation, and when available, a bronchoscopic lower respiratory tract culture that was obtained by bronchoscopy at the bedside of ICU. Obtained samples were cultured in a semi-quantitative manner.

An etiological diagnosis was made when a respiratory pathogen was isolated from a sterile specimen, a pneumococcal antigen was detected in urine, the antibody titers for an atypical pathogen increased 4-fold or converted to positive, or a predominant micro-organism was isolated from adequate sputa (\> 25 neutrophils and \< 10 squamous epithelial cells per low-power field) or bronchial washing or alveolar lavage fluids with compatible gram staining results. Methicillin-resistant *Staphylococcus aureus* (MRSA), drug-resistant strains of *Pseudomonas aeruginosa, Acinetobacter species, Stenotrophomonas maltophilia*, and extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae were considered to be MDR pathogens, as previously reported \[[@b13-kjim-2015-103]\].

Antibiotic therapy
------------------

Empirical antibiotic therapy was defined as the use of any antibiotics for \> 48 hours during the first 3 days of admission. Broad-spectrum antibiotics were defined as the use of any antibiotics that included anti-pseudomonal β-lactamase, vancomycin, or carbapenem.

Antibiotics therapy was initiated after at least blood culture samples were done because of severe condition requiring admission to ICU in basic accordance with the ATS/IDSA guideline \[[@b3-kjim-2015-103]\]. However, the detailed antibiotic regimen complied with the attending physician's choice taking into consideration patient's risk factors and the severity of the disease. The appropriateness of antibiotic therapy was analysed for all cases with an etiological diagnosis according to susceptibility test criteria for lower respiratory tract pathogens. Antibiotic therapy was classified as being inappropriate if the initially prescribed antibiotics were not directed at the identified pathogens, and treatment failure was defined as death during the initial treatment or poor treatment response. Poor treatment response defined as a change in the empirical antibiotics from the initial agents within the 7th day of the ICU admission.

Statistical analysis
--------------------

To compare the differences between the groups, Fisher exact tests were used for categorical variables, and the two-tailed *t* test, analysis of variance, or Mann-Whitney test was used for continuous variables, as appropriate. Statistical significance was established at a two-tailed *p* = 0.05. All analysis was conducted using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA).

RESULTS
=======

Baseline characteristics
------------------------

During the study period, 195 patients that required ICU care for pneumonia were eligible for the study: 75 with CAP (38.1%), 74 with HCAP (37.6%), and 46 with HAP (24.4%) ([Table 1](#t1-kjim-2015-103){ref-type="table"}). Distribution of HCAP were described in [Table 2](#t2-kjim-2015-103){ref-type="table"}, [Supplementary Table 1](#SD1){ref-type="supplementary-material"}, and HAP in [Supplementary Table 2](#SD2){ref-type="supplementary-material"}. Patients with HCAP were significantly more likely to have comorbidities, particularly cerebrovascular disease (55.4% vs. 30.7%, *p* = 0.009) and chronic kidney disease (16.2% vs. 1.3%, *p* = 0.002), than CAP patients. Leukopenia was also significantly more common in patients with HCAP than in those with CAP (23.0% vs. 5.3%, *p* = 0.005). There were no significant differences in pneumonia severity measured using the confusion, urea, respiratory rate, age ≥ 65 (CURB-65) criteria (≥ 3) and pneumonia severity index (PSI; high-risk class). Disease severity according to the Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment scores was similar across the three groups.

Pathogen distribution
---------------------

All of the patients had results of the gram staining and cultures of their blood and sputum. The number of bronchoscopic lower respiratory tract specimens was 44 in HCAP patients (61.1%), 50 in CAP patients (66.7%), and 23 in HAP patients (60.9%, *p* = 0.730). Bacterial pathogens were identified in 46 HCAP patients (62.2%), 37 CAP patients (46.3%), and 29 HAP patients (63.0%). [Table 3](#t3-kjim-2015-103){ref-type="table"} lists the frequency of each of the etiologic micro-organisms-for each group. The most common pathogens were methicillin-susceptible *Staphylococcus aureus* (MSSA) (29.7%), *Streptococcus pneumoniae* (13.5%), and *P. aeruginosa* (10.8%) in the CAP patients; Klebsiella pneumonia (45.6%), MRSA (19.6%), and Escherichia coli (15.3%) in the HCAP patients; and MRSA (44.8%), *P. aeruginosa* (24.1%), and *K. pneumonia* (24.1%) in the HAP patients.

In all three groups, *S. aureus* was the most common gram-positive pathogen. Of the *S. aureus* pathogens, MSSA was detected significantly more often in the CAP group than in the HCAP and HAP groups (*p* = 0.001). MRSA was detected at comparable rates in the CAP and HCAP groups and significantly more often in the HAP group (*p* = 0.002). Of the gram-negative pathogens, HCAP and HAP patients had significantly higher rates of ESBL-producing Enterobacteriaceae than the CAP patients (*p* = 0.015).

The prevalence of MDR pathogens in the HCAP group (39.1%) was significantly higher than in the CAP group (*p* \< 0.005) and lower than that in the HAP group (*p* = 0.001) ([Fig. 1](#f1-kjim-2015-103){ref-type="fig"}). Inappropriate initial antibiotic treatment was administered significantly less often in the CAP group (*p* = 0.034) than in the HCAP and HAP groups (*p* = 0.146).

Antimicrobial treatment and clinical outcomes
---------------------------------------------

In all three groups, the majority of the patients received combination antibiotic therapy as the initial treatment (CAP 86.7%, HCAP 78.4%, and HAP 71.7%) ([Table 4](#t4-kjim-2015-103){ref-type="table"}). Among the combination therapies, antipseudomonal β-lactamase in combination with fluoroquinolone was the most frequently used in HCAP and HAP (39.2% and 34.8%). β-Lactamase in combination with fluoroquinolone was the most common in CAP (34.6%). Among the monotherapies, antipseudomonal β-lactamase was the most frequently used in three groups (CAP 6.7%, HCAP 12.2%, and HAP 17.4%). Broad-spectrum antibiotics were administered to the CAP patients significantly less often than to the HCAP and HAP patients (*p* \< 0.05).

There were also no significant differences in clinical outcomes, including ICU mortality, 28-day mortality, length of ICU stay, and the duration of mechanical ventilation ([Table 5](#t5-kjim-2015-103){ref-type="table"}). The multiple logistic regression analysis resulted in a significantly increased odds of mortality associated with the acute physiologic PSI score and treatment response ([Table 6](#t6-kjim-2015-103){ref-type="table"}).

DISCUSSION
==========

Previous studies have compared bacteriological differences and clinical outcomes between HCAP and CAP, or between HCAP and HAP \[[@b1-kjim-2015-103],[@b14-kjim-2015-103]-[@b18-kjim-2015-103]\]. A study compared HCAP with CAP and HAP at the same time without mention of ICU admission \[[@b19-kjim-2015-103]\]. To our knowledge, this is the first report to compare the microbiologic epidemiology and clinical outcomes in patients admitted to the ICU with HCAP, to those with CAP and HAP. Three groups of pneumonia had similar baseline characteristics and pneumonia severity.

We identified the rate of MDR pathogens in the patients with HCAP was less than that in the patients with HAP and greater than that in patients with CAP as per the IDSA/ATS guidelines. However, the distribution of pathogens in the patients with HCAP was different from previous studies. Most common pathogen in HCAP reported previous studies was *S. aureus* or *S. pneumonia* \[[@b1-kjim-2015-103],[@b9-kjim-2015-103],[@b14-kjim-2015-103],[@b20-kjim-2015-103]\]. In our study, *K. pneumoniae* (45.6%) was the most common pathogen. Consequently, ESBL-producing *K. pneumoniae* was also the most common MDR pathogen. The incidence of MRSA in the HCAP group (19.6%) was similar to that in the CAP group (8.1%, *p* = 0.221) and lower than that in the HAP group (44.8%, *p* = 0.036). Similarly, one other study of microbial characteristics of HCAP and HAP in Korea showed similar microbial distribution. *K. pneumoniae* was the most common pathogen in HCAP group. The incidence of MRSA was lower than that of HAP group \[[@b21-kjim-2015-103]\]. The explanation for these differences is not clear. A study in residents of long-term care facilities reported that the most common pneumonia pathogens were gram-negative bacilli (18%) \[[@b22-kjim-2015-103]\]. Pop-Vicas and D'Agata \[[@b23-kjim-2015-103]\] noted the factors that were independently associated with the isolation of MDR gram-negative bacilli in these patients were an age \> 65 years, prior antibiotic therapy for \> 2 weeks, and residence in a long-term care facility. These are similar to the definition for HCAP.

The rate of initial administration of broad-spectrum antibiotics in the patients with HCAP and HAP were higher than those in patients with CAP as per the IDSA/ATS guidelines \[[@b3-kjim-2015-103]\]. Despite the more common use of broad spectrum antibiotics in the HCAP and HAP groups, the initial antibiotic treatment was inappropriate more frequently in the HCAP and HAP groups than in the CAP group. This difference may be explained by the differing prevalence of MDR pathogens between the groups. ESBL-producing *K. pneumoniae* was common in HCAP, whereas *Pseudomonas* spp. were less common in our study. According to our study, regional antimicrobial prescribing guidelines should contain the diversity in regional trends in microbial drug resistance.

Generally, the clinical course is poorer and the length of hospital stay is prolonged in patients with HCAP, compared to patients with CAP \[[@b1-kjim-2015-103],[@b6-kjim-2015-103],[@b8-kjim-2015-103]\]. Our study failed to show a significant difference in the clinical outcomes among the three groups because of the disease severity who were requiring ICU care by itself. Our study population was characterized by high severity of disease, approaching PSI stage IV and V disease. Overall mortality at 28 days was more than 20% in all of three groups. In one previous study that reported poorer clinical outcomes in patients with HCAP than that in those with CAP for low-risk patients, the mortality rates were not different for the high-risk patients \[[@b24-kjim-2015-103]\]. Especially, we did demonstrate that ICU mortality was associated with pneumonia severity. With similar disease severity, patients with CAP may demonstrate similar mortality as patients with HCAP or HAP, regardless of the presence of MDR pathogens.

Treatment response was another important factor for ICU mortality. Despite significant gradual differences among the groups in the rate of MDR pathogens and the presence of a high rate of broad-spectrum antibiotic use and inappropriate treatment in our study, there were no differences in the clinical outcomes including hospital length and mortality. Physician choice the initial antibiotics considering the risk factor of MDR pathogen or disease severity at the time of admission. There were no definite criteria for evaluating treatment response under treatments. It is critical to identify patients at risk for non-response pneumonia using defined criteria to institute early appropriate therapy. El Solh et al. \[[@b17-kjim-2015-103]\] evaluated treatment failure of severe pneumonia including nursing home residents. However, no specific definition of treatment failure was used. The parameters such as the PSI score, CURB-65, or APACHE II evaluate the severity of pneumonia at the time of admission and not response to treatment. We evaluated treatment response with definite criteria; a change in the empirical antibiotics from the initial agents within the 7th day of the ICU admission. The appropriate stewardship of antibiotics considering the treatment response could be more important factor influencing better clinical outcomes in this population.

The present study analysed data retrospectively within a single institution, which is a limitation. However, data were collected from a prospective cohort of patients who required ICU admission, and uniform methods were used to detect pathogens. Sputum and blood samples were evaluated for all of the patients, and \> 60% of the patients underwent a bronchoscopy to obtain specimens. Our successful pathogen identification rate of 57% (112/195) was high compared to the 20% to 50% reported in other prospectively designed studies \[[@b1-kjim-2015-103],[@b4-kjim-2015-103],[@b23-kjim-2015-103],[@b24-kjim-2015-103]\]. Second, prior antibiotic use in the HCAP group could not be accurately estimated due to insufficient information in the medical records from other clinics. In Korea, there are a wide variety of long-term health care facilities including assisted-living, rehabilitation, haemodialysis, and convalescent hospital facilities where antibiotics could be administered. Therefore, the number of patients in the HCAP subgroup ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) that were identified by the receipt of intravenous antibiotic therapy within 30 days of a current infection could have been underestimated. Finally, we excluded subsequent pneumonia events from patients who experienced ≥ 2 events in the same admission, potentially underestimating the number of HAP patients.

In conclusion, MDR pathogens were isolated in HCAP patients requiring ICU admission at intermediate rates between those of CAP and HAP. However, there were no significant differences among type of pneumonia in the clinical outcomes, including mortality.

KEY MESSAGE
===========

1\. Multidrug-resistant pathogens were isolated in healthcare-associated pneumonia patients requiring intensive care unit admission at intermediate rates between those of community-acquired pneumonia and hospital-acquired pneumonia.

2\. There were no significant differences among type of pneumonia in the clinical outcomes, including mortality.

3\. The mortality was associated with the acute physiologic pneumonia severity index score and treatment response.

No potential conflict of interest relevant to this article was reported.
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=======================

###### 

Subgroups of healthcare-acquired pneumonia

###### 

Subgroups of hospital-acquired pneumonia (n = 46)

![The distribution of multidrug-resistant (MDR) pneumonia pathogens in patients admitted to the intensive care unit for pneumonia, compared between three groups. CAP, community-acquired pneumonia; HCAP, healthcare-acquired pneumonia; HAP, hospital-acquired pneumonia; MRSA, methicillin-resistant *Staphylococcus aureus*; ESBL, extended-spectrum β-lactamase.](kjim-2015-103f1){#f1-kjim-2015-103}

###### 

Baselines characteristics of the study groups

  Characteristic                                                         CAP (n = 75)                                               HCAP (n = 74)   HAP (n = 46)                                              *p* value
  ---------------------------------------------------------------------- ---------------------------------------------------------- --------------- --------------------------------------------------------- -----------
  Age, yr                                                                72 (19--90)                                                73 (32--99)     75 (46--91)                                               0.409
  Male sex                                                               59 (78.7)                                                  56 (75.7)       38 (79.2)                                                 0.872
  Comorbidities                                                                                                                                                                                               
   Chronic lung disease^[a](#tfn1-kjim-2015-103){ref-type="table-fn"}^   29 (38.7)                                                  17 (23.0)       15 (31.3)                                                 0.117
   Chronic heart disease                                                 29 (38.7)                                                  32 (43.2)       24 (50.0)                                                 0.350
   Diabetes mellitus                                                     19 (31.7)                                                  24 (32.4)       17 (35.4)                                                 0.571
   Chronic liver disease                                                 5 (6.7)                                                    5 (6.8)         5 (10.4)                                                  0.655
   Chronic kidney disease                                                1 (1.3)^[a](#tfn1-kjim-2015-103){ref-type="table-fn"}^     12 (16.5)       9 (18.8)^[b](#tfn2-kjim-2015-103){ref-type="table-fn"}^   0.002
   Cerebrovascular disease                                               23 (30.7)^[c](#tfn3-kjim-2015-103){ref-type="table-fn"}^   41 (55.4)       21 (43.8)                                                 0.009
   Rheumatoid disease                                                    1 (1.3)                                                    2 (2.7)         0                                                         0.485
   Current malignancy                                                    7 (9.3)                                                    24 (32.4)       17 (37.0)                                                 0.095
  Radiographic finding                                                                                                                                                                                        
   Bilateral lung involvement                                            54 (72.0)                                                  51 (71.8)       27 (56.3)                                                 0.130
   Pleural effusion                                                      16 (21.3)                                                  18 (25.0)       18 (37.5)                                                 0.130
  Clinical parameters                                                                                                                                                                                         
   Leukopenia                                                            4 (5.3)                                                    17 (23.0)       5 (10.6)                                                  0.005
   C-reactive protein, mg/dL                                             16.3 ± 9.6                                                 15.6 ± 9.7      14.1 ± 8.1                                                0.440
   Procalcitonin, ng/mL                                                  12.5 ± 24.1                                                13.7 ± 28.0     33.5 ± 57.0                                               0.080
    ARDS                                                                 19 (25.7)                                                  11 (14.9)       12 (25.0)                                                 0.229
    Sepsis                                                               58 (77.3)                                                  66 (89.2)       42 (91.3)                                                 0.800
    Mechanical ventilation                                               66 (88.0)                                                  70 (94.3)       48 (100)                                                  0.613
    CRRT                                                                 15 (20.0)                                                  18 (24.3)       14 (29.2)                                                 0.132
  Severity                                                                                                                                                                                                    
   APACHE II                                                             25.1 ± 8.2                                                 27.1 ± 10.4     24.0 ± 8.0                                                0.152
   SOFA (day 1)                                                          8.8 ± 4.0                                                  9.89 ± 4.3      8.6 ± 4.1                                                 0.153
   PSI risk class ≥ IV                                                   67 (89.3)                                                  71 (95.9)       45 (97.8)                                                 0.108
   CURB-65 ≥ 3                                                           35 (49.0)                                                  41 (58.5)       24 (50)                                                   0.691

Values are presented as median (range), number (%), or mean ± SD.

CAP, community-acquired pneumonia; HCAP, healthcare-acquired pneumonia; HAP, hospital-acquired pneumonia; ARDS, acute respiratory distress syndrome; CRRT, continuous renal replacement therapy; APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, Sequential Organ Failure Assessment; PSI, pneumonia severity index; CURB-65, confusion, urea, respiratory rate, age ≥ 65.

*p* \< 0.05 when compared with HCAP.

*p* \< 0.05 when compared with CAP.

Chronic lung disease includes chronic obstructive lung disease and structural lung diseases, such as bronchiectasis.

###### 

Distribution of HCAP (n = 117)

  HCAP                                               Number
  -------------------------------------------------- --------
  1^[a](#tfn4-kjim-2015-103){ref-type="table-fn"}^   37
  2^[b](#tfn5-kjim-2015-103){ref-type="table-fn"}^   35
  3^[c](#tfn6-kjim-2015-103){ref-type="table-fn"}^   37
  4^[d](#tfn7-kjim-2015-103){ref-type="table-fn"}^   8

The numbers add up to more than the total, as many patients presented more than one HCAP criteria.

HCAP, healthcare-acquired pneumonia.

Hospitalization in an acute care hospital for 2 or more days within 90 days of the infection.

Infusion therapy, such as intravenous antibiotic therapy, chemotherapy, or wound care, within 30 days of a current infection.

Residence in a nursing home or long-term care facility.

Regular attendance at a dialysis clinic, including hemodialysis and peritoneal dialysis.

###### 

Distribution of the isolated pathogens in CAP, HCAP, and HAP patients

  Pathogen identified^[a](#tfn8-kjim-2015-103){ref-type="table-fn"}^                 CAP (n = 37)   HCAP (n = 46)                                               HAP (n = 29)                                                *p* value
  ---------------------------------------------------------------------------------- -------------- ----------------------------------------------------------- ----------------------------------------------------------- -----------
  Gram-positive pathogen                                                             21 (56.8)      17 (37.0)                                                   14 (48.3)                                                   0.193
   *Streptococcus pneumoniae*                                                        5 (13.5)       3 (6.5)                                                     0                                                           0.249
   Streptococci other than *S. pneumoniae*                                           3 (8.1)        2 (4.3)                                                     0                                                           0.285
   *Staphylococcus aureus*                                                           14 (37.8)      12 (26,1)                                                   13 (44.8)                                                   0.226
    MSSA                                                                             11 (29.7)      4 (8.7)                                                     0                                                           0.001
    MRSA                                                                             3 (8.1)        9 (19.6)                                                    13 (44.8)                                                   0.002
  Gram-negative pathogen                                                             18 (48.6)      35 (76.1)                                                   23 (79.3)                                                   0.009
   *Pseudomonas aeruginosa*                                                          4 (10.8)       5 (10.9)                                                    7 (24.1)                                                    0.212
   *Klebsiella pneumoniae*                                                           9 (23.3)       21 (45.6)                                                   7 (24.1)                                                    0.060
   *Escherichia coli*                                                                2 (5.4)        7 (15.3)                                                    4 (13.7)                                                    0.349
   *Enterobacter* spp.                                                               2 (5.4)        3 (6.5)                                                     3 (10.3)                                                    0.725
  MDR                                                                                5 (13.5)       18 (39.1)                                                   23 (79.3)                                                   \< 0.001
   MRSA                                                                              3 (8.1)        9 (19.6)                                                    13 (44.8)                                                   0.002
   ESBL producing *Enterobacteriae*^[b](#tfn9-kjim-2015-103){ref-type="table-fn"}^   1 (2.7)        10 (21.7)                                                   8 (27.6)                                                    0.015
   MDR-*Pseudomonas* spp.^[c](#tfn10-kjim-2015-103){ref-type="table-fn"}^            0              1 (2.2)                                                     2 (6.9)                                                     0.221
   CRAB                                                                              1 (2.7)        3 (6.5)                                                     4 (13.8)                                                    0.219
   *Stenotrophomonas maltophilia*                                                    1 (2.7)        0                                                           2 (6.9)                                                     0.200
  Inappropriate antibiotics treatment                                                4 (11.8)       15 (32.6)^[d](#tfn11-kjim-2015-103){ref-type="table-fn"}^   14 (51.7)^[d](#tfn11-kjim-2015-103){ref-type="table-fn"}^   0.006

Values are presented as number (%; no/patients with pathogen identified).

CAP, community-acquired pneumonia; HCAP, healthcare-acquired pneumonia; HAP, hospital-acquired pneumonia; MSSA, methicillin-susceptible *Staphylococcus aureus*; MRSA, methicillin-resistant *Staphylococcus aureus*; MDR, multidrug-resistant; ESBL, extended-spectrum β-lactamase; CRAB, carbapenem-resistant *Acinetobacter baumannii*.

Numbers include mixed population of pathogens (4 in CAP, 7 in HCAP, and 9 in HAP).

ESBL producing *Enterobacteriae* include *Klebsiella pneumoniae*, *Escherichia coli*, *Enterobacter* spp.

MDR *Pseudomonas* spp. means resistant *Pseudomonas aeruginosa*.

*p* \< 0.05 when compared with CAP.

###### 

Initial antibiotic treatment

  Empiric antibiotic                                                                         CAP (n = 75)   HCAP (n = 74)                                               HAP (n = 46)                                                *p* value
  ------------------------------------------------------------------------------------------ -------------- ----------------------------------------------------------- ----------------------------------------------------------- -----------
  Monotherapy                                                                                10 (13.3)      16 (21.6)                                                   13 (26.7)                                                   0.175
   β-Lactamase                                                                               4 (5.3)        2 (2.7)                                                     0                                                           0.254
   Antipseudomonal β-lactamase                                                               5 (6.7)        9 (12.2)                                                    8 (17.4)                                                    0.187
   Vancomycin                                                                                1 (1.3)        1 (1.4)                                                     0                                                           0.733
   Carbapenem                                                                                1 (1.3)        4 (5.4)                                                     4 (8.7)                                                     0.051
  Combination therapy                                                                        65 (86.7)      58 (78.4)                                                   33 (71.7)                                                   0.175
   β-Lactamase + Quinolone^[a](#tfn12-kjim-2015-103){ref-type="table-fn"}^                   26 (34.6)      7 (9.5)                                                     1 (2.2)                                                     \< 0.001
   β-Lactamase + Macrolide                                                                   1 (1.3)        0                                                           0                                                           0.449
   β-Lactamase + Clindamycin                                                                 6 (8.0)        8 (11.0)                                                    3 (6.5)                                                     0.568
   Antipseudomonal β-lactamase + Quinolone^[a](#tfn12-kjim-2015-103){ref-type="table-fn"}^   25 (33.3)      29 (39.2)                                                   16 (34.8)                                                   0.747
   Antipseudomonal β-lactamase + Vancomycin                                                  0              1 (1.4)                                                     3 (6.5)                                                     0.043
   Carbapenem + Quinolone^[a](#tfn12-kjim-2015-103){ref-type="table-fn"}^                    0              1 (1.4)                                                     0                                                           
   Vancomycin + Carbapenem                                                                   3 (4.0)        7 (9.5)                                                     8 (17.4)                                                    0.048
   Antipseudomonal β-lactamase + Quinolone + Vancomycin                                      1 (1.3)        4 (5.4)                                                     2 (4.3)                                                     0.392
  Others                                                                                     2 (2.6)        1 (1.4)                                                     1 (2.2)                                                     
  Broad spectrum antibiotics^[b](#tfn13-kjim-2015-103){ref-type="table-fn"}^                 32 (42.7)      47 (63.5)^[c](#tfn14-kjim-2015-103){ref-type="table-fn"}^   33 (71.7)^[c](#tfn14-kjim-2015-103){ref-type="table-fn"}^   0.003
  Treatment failure^[d](#tfn15-kjim-2015-103){ref-type="table-fn"}^                          15 (20.0)      26 (35.1)                                                   19 (41.3)                                                   0.076

Values are presented as number (%).

CAP, community-acquired pneumonia; HCAP, healthcare-acquired pneumonia; HAP, hospital-acquired pneumonia.

Quinolone was levofloxacin.

Broad spectrum antibiotic use was defined as the use of any antibiotics including antipseudomonal β-lactamase or vancomycin or carbapenem.

*p* \< 0.05 when compared with CAP.

Treatment failure means death during initial treatment or change of empirical antibiotics from the initial agents to others on the 7th day from medical intensive care unit admission.

###### 

Clinical outcomes of study populations

  Variable                                                                CAP (n = 75)    HCAP (n = 74)   HAP (n = 46)    *p* value
  ----------------------------------------------------------------------- --------------- --------------- --------------- -----------
  Duration, day                                                                                                           
   ICU                                                                    10.48 ± 11.9    11.0 ± 10.39    12.65 ± 11.20   0.321
   MV                                                                     10.15 ± 12.54   10.48 ± 10.89   12.44 ± 11.29   0.575
   Ventilator free days^[a](#tfn16-kjim-2015-103){ref-type="table-fn"}^   2.0 ± 1.90      2.8 ± 5.87      2.06 ± 2.69     0.662
   ICU free days^[b](#tfn17-kjim-2015-103){ref-type="table-fn"}^          14.0 ± 29.9     27.9 ± 29.0     39.7 ± 27.7     0.831
  Mortality                                                                                                               
   ICU mortality                                                          21 (28.0)       20 (27.0)       20 (43.5)       0.124
   28-Day mortality                                                       26 (38.2)       22 (32.8)       14 (31.1)       0.694

Values are presented as mean ± SD or number (%).

CAP, community-acquired pneumonia; HCAP, healthcare-acquired pneumonia; HAP, hospital-acquired pneumonia; ICU, intensive care unit; MV, mechanical ventilation.

A total of 92 patients were successfully weaned from mechanical ventilation in the ICU.

ICU free days refers to the period from ICU discharge to hospital discharge.

###### 

Results of the logistic regression analysis to determine the factors associated with mortality

  Predictor                                                                 OR     95% CI       *p* value
  ------------------------------------------------------------------------- ------ ------------ -----------
  Male sex                                                                  1.88   0.64--5.49   0.249
  Age, yr                                                                   1.03   0.99--1.08   0.151
  CAP^[a](#tfn18-kjim-2015-103){ref-type="table-fn"}^                       1.41   0.54--3.67   0.477
  HAP                                                                       1.80   0.63--5.15   0.270
  PSI                                                                       1.01   1.00--1.03   0.036
  MDR pathogens                                                             0.45   0.15--1.10   0.142
  Poor treatment response^[b](#tfn19-kjim-2015-103){ref-type="table-fn"}^   3.51   1.57--9.24   0.003

OR, odds ratio; CI, confidence interval; CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia; PSI, pneumonia severity index; MDR, multidrug-resistant.

Compared with healthcare-acquired pneumonia.

Change of empirical antibiotics from initial agents to others within the 7th day.
